In conclusion, unraveling the involvement of DCs in MDS pathogenesis will provide a better understanding of the immune dysregulation mechanisms that are present in this disease. The phenotypical and ...
Somatically acquired genetic abnormalities lead to the salient features that define myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation, peripheral cytopenias, and risk of ...
Determining the roles that various inflammatory markers and pathways play in lower-risk myelodysplastic syndromes (MDS) could lead to therapies that keep disease progression at bay. This team ...
A study identifies TET2–GFI1 axis as a critical brake suppressing malignant transformation of hematopoietic stem cells in myelodysplastic syndromes Published on April 01, 2026, in Volume 2, article ...
Infection is the leading cause of death in LR-MDS patients, responsible for 24.6% of deaths within a year of diagnosis. Key risk factors for infection include intermediate or higher IPSS-R risk, ...
Myelodysplastic syndromes (MDS) are a group of blood cancers that affect the bone marrow and can result in a low levels of blood cells. When MDS affects red blood cells, it can lead to anemia in some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results